

GLAXOSMITHKLINE PLC

Form 6-K

October 01, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending October 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc (the 'Company').

On 30 September 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £12.51 per Ordinary Share, and notional ADSs at a price of \$37.86 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2015 to 30 September 2015:

Non Executive Director	Ordinary Shares	No. of ADSs
Sir Philip Hampton	3,497.202	
Professor Sir Roy Anderson	574.540	
Dr Stephanie Burns	757.793	
Stacey Cartwright	424.660	
Lynn Elsenhans		1,552.170
Judy Lewent		587.943
Sir Deryck Maughan		1,829.157
Dr Daniel Podolsky		1,371.868
Urs Rohner	524.580	
Hans Wijers	424.660	

The Company and the Non-Executive Directors were informed of these allocations on 1 October 2015.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Company Secretary

1 October 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 01, 2015

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc